[Featured Stock] Humedics Forecasts Record Quarterly Sales Driven by Overseas Fillers

Humedix's stock price is on the rise. Expectations that quarterly sales will reach an all-time high due to strong overseas filler sales appear to be influencing the stock price.

At 10:25 a.m. on the 11th, Humedix was trading at 33,500 KRW, up 7.03% from the previous day.

Lee Dong-geon, a researcher at SK Securities, explained, "In the first quarter results this year, as filler production normalizes, overseas filler sales as well as domestic sales are expected to increase significantly compared to the same period last year. In particular, overseas filler sales are estimated to reach an all-time high due to the effect of entering new regions." He added, "Considering the 'low in the first half, high in the second half' pattern of overseas sales, the operating profit margin is also expected to rise gradually after hitting the bottom in the first quarter of this year."

Researcher Lee continued, "Significant sales growth has been observed not only in Brazil and China but also in newly entered countries such as Southeast Asia, the Middle East, and Russia," adding, "The current stock price is trading at a price-to-earnings ratio (PER) of 8.8 times for this year’s forecast. Considering the rebound trend in the stock prices of aesthetic medical device companies, this represents a significant undervaluation."

This content was produced with the assistance of AI translation services.